Kexing Biopharm Co., Ltd.
Quick facts
Phase 3 pipeline
- Human interferon α1b Inhalation Solution · Immunology / Infectious Disease
Human interferon α1b activates innate immune responses by binding to interferon-alpha receptors on immune and epithelial cells, enhancing antiviral and immunomodulatory activity.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Kexing Biopharm Co., Ltd.
What is Kexing Biopharm Co., Ltd.'s pipeline?
Kexing Biopharm Co., Ltd. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Human interferon α1b Inhalation Solution.
Related
- Sector hub: All tracked pharma companies